The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Chronic Inflammation in Cancer Development
Open accessAbstract
Chronic inflammatory mediators exert pleiotropic effects in the development of cancer. On the one hand, inflammation favors carcinogenesis, malignant transformation, tumor growth, invasion, and metastatic spread; on the other hand inflammation can stimulate immune effector mechanisms that might limit tumor growth. The link between cancer and inflammation depends on intrinsic and extrinsic pathways. Both pathways result in the activation of transcription factors such as NF-κB, STAT-3, and HIF-1 and in accumulation of tumorigenic factors in tumor and microenvironment. STAT-3 and NF-κB interact at multiple levels and thereby boost tumor-associated inflammation which can suppress anti-tumor immune responses. These factors also promote tumor growth, progression, and metastatic spread. IL-1, IL-6, TNF, and PGHS-2 are key mediators of an inflammatory milieu by modulating the expression of tumor-promoting factors. In this review we concentrate on the crucial role of pro-inflammatory mediators in inflammation-driven carcinogenesis and outline molecular mechanisms of IL-1 signaling in tumors. In addition, we elucidate the dual roles of stress proteins as danger signals in the development of anti-cancer immunity and anti-apoptotic functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–240 of 240
Heat Shock Protein as Molecular Targets for Breast Cancer Therapeutics
Kim, L. S., & Kim, J. H. (2011) · Journal of Breast Cancer · doi:10.4048/jbc.2011.14.3.167 · Cited by 63
Cross, S. S., Harrison, R. F., Balasubramanian, S. P., Lippitt, J. M., Evans, C. A., Reed, M., & Holen, I. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.030031 · Cited by 63
Role of IL-1-Mediated Inflammation in Tumor Angiogenesis
Voronov, E., Carmi, Y., & Apte, R. N. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72005-0_28 · Cited by 62
Botzler, C., Schmidt, J., Luz, A., Jennen, L., Issels, R. D., & Multhoff, G. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980911)77:6<942::aid-ijc25>3.0.co;2-1 · Cited by 62
Self-citationRaut, C. P., Nawrocki, S. T., Lashinger, L. M., Davis, D. W., Khanbolooki, S., Xiong, H. Q., Ellis, L. M., & McConkey, D. J. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.12.1221 · Cited by 61
Li, X., Kim, K., Cho, M., Ju, J., Kang, C., Oh, H.-J., Min, J., Lee, S., Park, S., & Kim, H. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.10.012 · Cited by 61
Angst, E., Reber, H. A., Hines, O. J., & Eibl, G. (2008) · Surgery · doi:10.1016/j.surg.2008.03.024 · Cited by 59
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Shephard, R. J. (2011) · Yearbook of Sports Medicine · doi:10.1016/j.yspm.2011.03.009 · Cited by 59
Tseng, W. W., Deganutti, A., Chen, M. N., Saxton, R. E., & Liu, C. D. (2002) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(02)00061-6 · Cited by 58
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., et al. (2009) · The Journal of Cell Biology · doi:10.1083/jcb1861oia2 · Cited by 56
Cytokines Are a Therapeutic Target for the Prevention of Inflammation-Induced Cancers
Rose‐John, S., & Schooltink, H. (2007) · Springer eBooks · doi:10.1007/978-3-540-37696-5_5 · Cited by 55
Stangl, S., Wortmann, A., Gürtler, U., & Multhoff, G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.6270 · Cited by 53
Self-citationHedrich, C. M., Brück, N., Fiebig, B., & Gahr, M. L. (2011) · Rheumatology International · doi:10.1007/s00296-011-2249-4 · Cited by 50
Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells
Tang, Z.-N., Zhang, F., Tang, P., Qi, X., & Jiang, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.035 · Cited by 49
Sansone, P., Piazzi, G., Paterini, P., Strillacci, A., Ceccarelli, C., Minni, F., Biasco, G., Chieco, P., & Bonafè, M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00580.x · Cited by 48
Multhoff, G., Pfister, K., Botzler, C., Jordan, A., Scholz, R., Schmetzer, H. M., Burgstahler, R., & Hiddemann, W. (2000) · International Journal of Cancer · Cited by 46
Self-citationJurado, S., García‐Giralt, N., Díez‐Pérez, A., Esbrit, P., Yoskovitz, G., Águeda, L., Urreizti, R., Pérez-Edo, L., Saló, G., Mellibovsky, L., et al. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22538 · Cited by 46
Rudner, J., Elsässer, S. J., Müller, A., Belka, C., & Jendrossek, V. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.07.021 · Cited by 42
Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?
Spektor, G., & Fuster, V. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0214 · Cited by 41
Expression of Osteoprotegerin and RANK Ligand in Breast Cancer Bone Metastasis
Park, H. R., Min, S. K., Cho, H. D., Kim, D. H., Shin, H. S., & Park, Y. E. (2003) · Journal of Korean Medical Science · doi:10.3346/jkms.2003.18.4.541 · Cited by 41
Combinatorial effect of epigallocatechin-3-gallate and TRAIL on pancreatic cancer cell death
Basu (1992) · International Journal of Oncology · doi:10.3892/ijo_00000150 · Cited by 39
Hoffmann, J., Junker, H., Schmieder, A., Venz, S., Brandt, R., Multhoff, G., Falk, W., & Radons, J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.063 · Cited by 38
Self-citationInhibiting IL-6 in Human Multiple Myeloma
Klein, B., Lu, Z., Gaillard, J., Harousseau, J., & Bataille, R. (1992) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-77633-5_29 · Cited by 36
The Interleukin 1 (IL-1) Receptor Accessory Protein Toll/IL-1 Receptor Domain
Radons, J., Dove, S., Neumann, D., Altmann, R., Botzki, A., Martin, M. U., & Falk, W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306077200 · Cited by 36
Self-citationAssessment of celecoxib pharmacodynamics in pancreatic cancer
Jimeno, A., Amador, M. L., Kulesza, P., Wang, X., Rubio‐Viqueira, B., Zhang, X., Chan, A., Wheelhouse, J., Kuramochi, H., Tanaka, K., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0565 · Cited by 33
Atreya, R. N., Atreya, I., & Neurath, M. F. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1326.001 · Cited by 32
Yamada, T., Tsuda, M., Takahashi, T., Totsuka, Y., Shindoh, M., & Ohba, Y. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.02.003 · Cited by 32
Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo.
Weiss, T. W., Simak, R., Kaun, C., Rega‐Kaun, G., Pflüger, H., Maurer, G., Huber, K., & Wojta, J. (2011) · PubMed · Cited by 32
Ng, P. K., Tsui, S. K., Lau, C., Wong, C. H., Wong, W. H., Huang, L., & Kumta, S. M. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22556 · Cited by 32
Sun, S., Lau, Y., Itonaga, I., Sabokbar, A., & Athanasou, N. (2006) · The Journal of Pathology · doi:10.1002/path.1953 · Cited by 31
Radons (2009) · International Journal of Oncology · doi:10.3892/ijo_00000317 · Cited by 30
Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma
Alshamsan, A. (2011) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2011.625034 · Cited by 24
Taketomi, A., Takenaka, K., Matsumata, T., Shimada, M., Higashi, H., Shirabe, K., Itasaka, H., Adachi, E., Maeda, T., & Sugimachi, K. (1997) · PubMed · Cited by 24
Downward, J. (2009) · Nature · doi:10.1038/462044a · Cited by 21
Gersh, B. J. (2009) · Yearbook of Medicine · doi:10.1016/s0084-3873(09)79449-0 · Cited by 21
Signalling networks, inflammation and innate immunity
Dower, S. K., & Qwarnstrom, E. E. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311462 · Cited by 18
Schulze, J., Albers, J., Baranowsky, A., Keller, J., Spiro, A. S., Streichert, T., Zustin, J., Amling, M., & Schinke, T. (2009) · Bone · doi:10.1016/j.bone.2009.09.024 · Cited by 16
Hwang, W., Jung, K., Jeon, Y., Yun, S., Kim, T. W., & Choi, I. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.027 · Cited by 15
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk
Lee, Y. H., Ji, J. D., & Song, G. G. (2006) · Rheumatology International · doi:10.1007/s00296-006-0244-y · Cited by 15
Fernández, M., Pino, A. M., Figueroa, P., & Rodríguez, J. P. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22676 · Cited by 11
Cited by
Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,099
Global Impacts of Western Diet and Its Effects on Metabolism and Health: A Narrative Review
Clemente-Suárez, V. J., Beltrán-Velasco, A. I., Redondo-Flórez, L., Martín-Rodríguez, A., & Tornero-Aguilera, J. F. (2023) · Nutrients · doi:10.3390/nu15122749 · Cited by 804
Regulation of Immunity and Inflammation by Hypoxia in Immunological Niches
Taylor, C. T., & Colgan, S. P. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.103 · Cited by 713
Yang, Y., Wu, C., Hsu, P., Chen, S., Huang, S., Chan, W. L., Lin, S., Chou, C., Chen, J., Pan, J., et al. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13230 · Cited by 692
Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics
Chamoli, A., Gosavi, A. S., Shirwadkar, U. P., Wangdale, K. V., Behera, S. K., Kurrey, N. K., Kalia, K., & Mandoli, A. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105451 · Cited by 589
Metadata
- Authors
- Multhoff, G., Molls, M., & Radons, J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 2
- Pages
- 98-98
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W1984752955
- Cited by
- 576
- References
- 240
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.